Student
Location: Stanford, California, United States United States
Founded in: 2019
Stage: Pre-launch
Number of employees: 1-5
Short URL: vator.co/faceprint-1
Vatorx1

FacePrint

Startup/business
Stanford, California, United States United States
http://projectfaceprint.com
  • About
Company description

FacePrint is an early detection and monitoring tool for neurological and psychological disorders using video technology and facial expression impairments. FacePrint digitizes and objectively captures non-verbal communication and emotions, providing indicators of disease onset and progression. Initially developed and validated for Parkinson's disease and commonly misidentified degenerative disorders, FacePrint is currently being developed for a variety of mental and behavioral health disorders, starting with OCD and PTSD. Ultimately, FacePrint can be combined with brain imaging and other deep phenotyping technology to develop a comprehensive map and taxonomy of mental health conditions and to identify different subtypes and optimal treatment strategies. FacePrint hopes to be one piece of the larger puzzle of building the future of mental healthcare that is objective, personalized, and preemptive.




Team
Business model

FacePrint can be used by healthcare providers as an objective screening and monitoring tool for different mental health conditions. FacePrint can also help augment clinical visits with psychiatrists and therapists and provide objective measurements that correspond to clinical measures and supplement the provider’s own observations. Further, FacePrint can be used by pharmaceutical companies to help test and develop novel therapeutics. FacePrint can also be used by telemedicine providers to have richer insights and a more comprehensive understanding of the patient’s state and symptoms. Ultimately, FacePrint could also be built out into an asynchronous telepsychiatry platform.

Competitive advantage

FacePrint is a patent-pending technology that has been developed and validated through two initial pilot studies and is currently undergoing clinical trials with Stanford Medical School and the Michael J. Fox Foundation for Parkinson’s disease. Currently, there is a deficit of affective computing companies in the healthcare space. We aim to be a pioneer in the field- combining the clinical and technical expertise necessary to succeed. We hope that the Lab will help us further level up and gain the critical clinical insights and partnerships needed to build out the technology and to develop a robust business model to sustain the innovation.